A high level contact group has been set up to address European Union industry concerns about meeting the November 30, 2010, deadline under REACH for registration of chemicals that are produced in high volumes and/or are most hazardous.
The EU's REACH chemical legislation affects the drug industry, as it covers all substances for synthesis or processing used in the manufacture of pharmaceuticals.
According to the REACH Regulation, failure to register by the deadline means that a substance cannot be used or put on the market. The group, called the Directors' Contact Group, met for the first time on February 5 in Brussels. The group consists of director-level representatives from the European Commission, the European Chemicals Agency and from the industry associations CEFIC, Eurometaux, REACH Alliance, Concawe, FECC and UEAPME.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze